A trial of THR-317 in combination therapy with anti-VEGF treatments to treat diabetic macular edema.
Phase of Trial: Phase II
Latest Information Update: 20 Oct 2017
At a glance
- Drugs THR 317 (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 20 Oct 2017 According to a ThromboGenics media release, results are expected during Q1 2018.
- 10 Jul 2017 According to a BioInvent International media release, first patient was enrolled in Jan 2017.
- 10 Jul 2017 Status changed from planning to recruiting,according to a BioInvent International media release.